MARKET WIREYahoo Finance • 17h ago
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
Why AVTR Stock dropped -3.78% Today — RQD Quant Desk Flash
$16.05 -3.78% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.91
Avantor Inc. (AVTR) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $10.88B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AVTR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $16.05 (-3.78% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, AVTR ranks #195 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AVTR compare to BIO and TXG in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AVTR?
▼
Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.91 (-0.87%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTR)Realized 20D OHLCV Swing Band: ±6.3%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY AVTR SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (27% of score)
20D Institutional Volume Accumulation (±6.3% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (20% of score)
FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)
Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$15.70+9.9% Next Q
48
Q2 (-2Q)Grade C-$17.26-3.3% Next Q
51
Q3 (-1Q)Grade C-$16.69-3.8% Next Q
53
CurrentGrade D+$16.05-0.4% Hist 90D α
56
Trajectory: D (48) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AVTR Bull Thesis Could Fail
Even with a 56/100 (D+) score, AVTR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 30.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.62) or 200D SMA ($11.26) invalidates the momentum regime and cuts Target Base ($15.91) toward Bear Floor ($12.41).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AVTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AVTR Stock dropped -3.78% Today — RQD Quant Desk Flash
Avantor Inc. (AVTR) dropped -3.78% to $16.05, trading at 86% of its 52-week range ($7.26 – $17.45). Stretched risk/reward at current multiples (-2% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 86% of its 52-week range ($7.26 – $17.45) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.3% around $16.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 32.7% gross margin and $495.0M annual free cash flow.
Live AVTR Headlines & Catalysts
CATALYSTYahoo Finance • 20h ago
Avantor (AVTR) is Regaining Market ConfidenceYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 23h ago
Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value SaysGuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year FallSimply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets CautionYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Here's Why You Should Add Avantor Stock to Your Portfolio for NowYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
3 Reasons to Sell AVTR and 1 Stock to Buy InsteadYahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 16h ago
Cell and Tissue Culture Supplies - Global Strategic Business Report: Capitalize on the US$97.7 Billion Surge as Avantor, Corning, Lonza, and Thermo Fischer Scientific Reshape CompetitionBoost ROI through automation, 3D culture and specialty media that enhance throughput, reproducibility and drug-screening accuracy while reducing manual work and animal testing.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "C
MARKET WIREYahoo • 3d ago
Avantor, Inc. (AVTR) is a Great Momentum Stock: Should You Buy?Does Avantor, Inc. (AVTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVTR)
- ✓Walkthrough of AVTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AVTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +100.88%🛡️ HOLDING TREND SUPPORT
2026-11-03O $16.68H $16.68L $16.05C $16.05VOL 9.73M
RES: $17.87SUP: $16.08SMA50: $15.62SMA200: $11.26
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AVTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.9%/yr Implied 5Y Growth
vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AVTR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AVTR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AVTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTR)
Health Care Rank #195 of 1016
⚔️ BIO vs AVTR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AVTR vs. BIO, TXG, BRKR, RVTY)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Avantor Inc. (AVTR) ranks #195 by composite RQD confidence (56/100, grade D+) and #99 by equity capitalization ($10.88B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with AVTR at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVTR
ACTIVE
Avantor Inc. | D+ | 56/100 | — | 32.7% | -2.1% | -3.78% | $10.88B | Benchmark Subject |
| BIO Bio-Rad Laboratories Inc. | C | 62/100 | 13.5x | 51.9% | 0.5% | -3.18% | $9.95B | /bio-vs-avtr → |
| TXG 10x Genomics Inc. | C- | 59/100 | — | 69.1% | -5.7% | -14.03% | $9.13B | /txg-vs-avtr → |
| BRKR Bruker Corporation | D+ | 54/100 | — | 45.9% | 1.3% | -7.95% | $8.70B | /brkr-vs-avtr → |
| RVTY Revvity Inc. | C | 65/100 | 76.7x | — | 3.1% | -5.30% | $17.52B | /rvty-vs-avtr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001722482In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avantor Inc. (AVTR) reported GAAP revenue of $6.55B (-3.4% vs. FY2024 revenue of $6.78B , and -6.0% cumulative change since FY2023) , GAAP net income of -$530.2M, operating cash flow of $623.8M, and free cash flow of $495.0M (-28.5% YoY). On the balance sheet, AVTR closed FY2025 with $11.79B in total assets against $3.92B in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.55B | -$530.2M | $623.8M | $495.0M | $11.79B | $3.92B |
| FY2024 (FY) | 2024-12-31 | $6.78B | $711.5M | $840.8M | $692.0M | $12.11B | $3.23B |
| FY2023 (FY) | 2023-12-31 | $6.97B | $321.1M | $870.0M | $556.5M | $8.36B | $1.96B |
3. AVTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $16.05 (-3.78% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, AVTR ranks #195 in composite RQD confidence.
How does AVTR compare to BIO and TXG in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AVTR?
Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AVTR trading relative to its 50-day, 200-day, and 52-week technical levels?
AVTR last traded at $16.05 (-3.78% on volume of 9,733,870 shares), positioning the stock +2.75% above its 50-day simple moving average ($15.62) and +42.54% above its 200-day simple moving average ($11.26). Across its 52-week range of $7.26 to $17.45, AVTR sits at the 86.3% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.3% ($15.04 to $17.06).
AVTR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AVTR stock moving today?
Why AVTR Stock dropped -3.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-2% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 56/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AVTR — Avantor Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:56Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AVTR scores 59 out of 100, equating to a C- grade and the verdict "Roarable Hold — Cautious Neutral." The five pillars are:
- Fundamental Cash Engine (10/20): Per the RQD rating, this pillar reflects ROIC of -2.1% and an FCF yield of 4.38%. Negative ROIC means the business is not currently earning returns above its capital base, a meaningful drag on this pillar. The positive FCF yield indicates the company still generates cash relative to its market value, which partially offsets the weak return profile.
- Whale 13F Flow (18/20): This is the strongest pillar, described per the RQD rating as reflecting institutional accumulation and options positioning. For a prospective investor, this suggests larger holders have been building or maintaining positions, a potential support factor. The underlying 13F holder detail itself is not provided in the source data.
- Insider Conviction (11/20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow at a moderate level. Mid-range insider signal suggests neither strong insider buying conviction nor significant selling pressure.
- Macro Regime Fit (11/20): Per the RQD rating, beta is 1.01, meaning the stock has moved roughly in line with the market. Sector sensitivity is noted but not further quantified in the source data. Investors should expect returns to track broader market and sector conditions.
- Forensic Balance Sheet (9/20): Per the RQD rating, Altman Z is 1.88, Piotroski F is 5/9, and Debt/Equity is 0.7. A Z-score in this range is commonly viewed as a financial-distress caution zone; the Piotroski score is moderate. This is the second-weakest pillar and a central risk consideration.
Investor implications: The rating points to a mixed picture. Upside drivers include institutional positioning and the positive FCF yield. Valuation tradeoffs are significant: the forward P/E of 31 is elevated relative to the negative trailing EPS of -0.78, and P/E (TTM) is not available in source data, so the valuation rests heavily on expectations of earnings recovery. The balance sheet and negative returns on capital are the principal headwinds. The verdict of "Cautious Neutral" reflects this balance rather than a directional call.
Business
Avantor Inc. is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry, per the profile. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data. Specifics on product lines, customer segments, and revenue mix are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $6552.2M | $-246.2M | $-530.2M | N/A | $495.0M | $365.4M | $3915.5M |
| FY 2024 | $6783.6M | $1084.8M | $711.5M | N/A | $692.0M | $261.9M | $3234.7M |
| FY 2023 | $6967.2M | $696.4M | $321.1M | N/A | $556.5M | N/A | $1956.4M |
Per the SEC financials, revenue declined from $6967.2M (FY 2023) to $6552.2M (FY 2025), and FY 2025 moved to an operating loss of $-246.2M and net loss of $-530.2M after positive results in FY 2024. Operating margin is -3.8% and net margin is -8.1% per market data. ROIC is -2.1%. Per the RQD rating, the Altman Z-Score is 1.88 and the Piotroski F-Score is 5/9. Debt rose from $1956.4M (FY 2023) to $3915.5M (FY 2025), and Debt/Equity is 0.7 per the RQD rating.
Recent Catalysts & News Wire Analysis
- Market wire (YELLOW): "Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?" — Yahoo Finance.
- Catalyst (GREEN): "Avantor (AVTR) is Regaining Market Confidence" — Yahoo Finance.
- Market wire (YELLOW): "Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28" — Seeking Alpha.
- Catalyst (GREEN): "Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says" — GuruFocus.
- Risk watch (RED): "Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall" — Simply Wall St.
- Risk watch (RED): "Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution" — Yahoo Finance.
Per the news feed, catalyst items are mixed: two positive catalysts, two market-wire items, and two risk-watch items referencing the Q3 earnings reaction and the five-year decline. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.
Open Questions
- What drove the swing from FY 2024 net income of $711.5M to FY 2025 net loss of $-530.2M, and is it recurring or one-time?
- What is the trailing P/E and EV/EBITDA, given both are unavailable in source data while forward P/E is 31?
- How much of the $3915.5M debt load is near-term maturity, and what is the refinancing profile?
- What are the drivers of the 13F accumulation signal, and which institutions are involved?
- What is the FY 2025 EPS, which is reported as N/A?
AVTR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Avantor Inc. (AVTR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 17h ago
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year? Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 20h ago
Avantor (AVTR) is Regaining Market Confidence Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 23h ago
Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28 Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says GuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall Simply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Here's Why You Should Add Avantor Stock to Your Portfolio for Now Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
3 Reasons to Sell AVTR and 1 Stock to Buy Instead Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AVTR Bull vs. Bear Conversation Board — What's Your Call at $16.05?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTR 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $18.01 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AVTR (C- • RQD 59/100) a Buy at $16.68?
Welcome to the AVTR (Avantor Inc.) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $12.51 (-25.0%)
Spot @ $16.68 Pump the brakes on AVTR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AVTR, but look at what you are paying: current EV/EBITDA multiples with 32.7% gross margins. Unless Avantor Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $20.52 (+23.0%)
Spot @ $16.68 AVTR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AVTR, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $16.68 (52-wk range $7.26 - $17.45), any beat on forward guidance forces shorts and underweight funds to chase.